Giant Biogene Holding Co., Ltd.

SEHK:2367 Voorraadrapport

Marktkapitalisatie: HK$49.6b

Giant Biogene Holding Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jianya Yan

Algemeen directeur

CN¥11.9m

Totale compensatie

Percentage CEO-salaris5.1%
Dienstverband CEO2.6yrs
Eigendom CEO0.09%
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuur2.1yrs

Recente managementupdates

Recent updates

Giant Biogene Holding Co., Ltd. (HKG:2367) Shares Could Be 50% Below Their Intrinsic Value Estimate

Nov 20
Giant Biogene Holding Co., Ltd. (HKG:2367) Shares Could Be 50% Below Their Intrinsic Value Estimate

Revenue Beat: Giant Biogene Holding Co., Ltd. Beat Analyst Estimates By 12%

Aug 21
Revenue Beat: Giant Biogene Holding Co., Ltd. Beat Analyst Estimates By 12%

Does Giant Biogene Holding (HKG:2367) Deserve A Spot On Your Watchlist?

Aug 09
Does Giant Biogene Holding (HKG:2367) Deserve A Spot On Your Watchlist?

Giant Biogene Holding Co., Ltd.'s (HKG:2367) Popularity With Investors Is Clear

Jul 01
Giant Biogene Holding Co., Ltd.'s (HKG:2367) Popularity With Investors Is Clear

Is Giant Biogene Holding Co., Ltd. (HKG:2367) Trading At A 32% Discount?

Apr 17
Is Giant Biogene Holding Co., Ltd. (HKG:2367) Trading At A 32% Discount?

Investors Interested In Giant Biogene Holding Co., Ltd.'s (HKG:2367) Earnings

Mar 28
Investors Interested In Giant Biogene Holding Co., Ltd.'s (HKG:2367) Earnings

Giant Biogene Holding Co., Ltd. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

Mar 27
Giant Biogene Holding Co., Ltd. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

Do Giant Biogene Holding's (HKG:2367) Earnings Warrant Your Attention?

Dec 24
Do Giant Biogene Holding's (HKG:2367) Earnings Warrant Your Attention?

A Look At The Intrinsic Value Of Giant Biogene Holding Co., Ltd. (HKG:2367)

Oct 30
A Look At The Intrinsic Value Of Giant Biogene Holding Co., Ltd. (HKG:2367)

Giant Biogene Holding Co., Ltd.'s (HKG:2367) Share Price Matching Investor Opinion

Mar 28
Giant Biogene Holding Co., Ltd.'s (HKG:2367) Share Price Matching Investor Opinion

Analyse CEO-vergoeding

Hoe is Jianya Yan's beloning veranderd ten opzichte van Giant Biogene Holding's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

CN¥2b

Mar 31 2024n/an/a

CN¥2b

Dec 31 2023CN¥12mCN¥606k

CN¥1b

Sep 30 2023n/an/a

CN¥1b

Jun 30 2023n/an/a

CN¥1b

Mar 31 2023n/an/a

CN¥874m

Dec 31 2022CN¥10mCN¥600k

CN¥696m

Dec 31 2021CN¥10mCN¥600k

CN¥809m

Compensatie versus markt: De totale vergoeding ($USD 1.64M ) Jianya } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 791.09K ).

Compensatie versus inkomsten: De vergoeding van Jianya is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jianya Yan (58 yo)

2.6yrs

Tenure

CN¥11,885,000

Compensatie

Mr. Jianya Yan is Co-Founder of Giant Biogene Holding Co., Ltd., serves as its Chief Executive Officer, Executive Director & Chairman of the Board since April 21, 2022 and served as its Director since Nove...

Bestuursleden

NaamPositieTenureCompensatieEigendom
Jianya Yan
CEO & Executive Chairman of the Board3yrsCN¥11.89m0.089%
HK$ 44.2m
Huijuan Zhang
CFO & Executive Director1.1yrsCN¥241.00kgeen gegevens
Juan Ye
Senior VP & Executive Director3yrsCN¥1.82mgeen gegevens
Juan Fang
Senior VP & Executive Director3yrsCN¥2.11mgeen gegevens
Yubo Yan
Chief Product Officer1.1yrsCN¥140.00kgeen gegevens
Sze Wing Wong
Independent Non-Executive Director2.1yrsCN¥180.00kgeen gegevens
Wenhua Shan
Independent Non-Executive Director2.1yrsCN¥108.00kgeen gegevens
Jin Huang
Independent Non-Executive Director2.1yrsCN¥108.00kgeen gegevens

2.1yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2367 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.1 jaar), wat duidt op een nieuw bestuur.